Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Nedaplatin]

K Ota1

  • 1Nagoya Memorial Hospital, Nagoya, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Nedaplatin, a cisplatin derivative, shows promising efficacy with reduced toxicity in various cancers. Phase II studies indicate significant response rates, with approved indications for several tumor types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental and clinical studies on dysregulation of magnesium metabolism and the aetiopathogenesis of multiple sclerosis.

Magnesium research·1992
Same author

Mechanism of proteinuria in nephrotic syndrome.

Acta medica Okayama·1992
Same author

Effects of nicergoline on calcium and magnesium deposition in the central nervous system tissues of rats maintained on low-calcium diets.

The Journal of international medical research·1992
Same author

Alpha 2-adrenergic receptors are involved in the suppression of luteinizing hormone release during acute fasting in the ovariectomized estradiol-primed rats.

Neuroendocrinology·1992
Same author

[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].

Gan to kagaku ryoho. Cancer & chemotherapy·1992
Same author

[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].

Gan to kagaku ryoho. Cancer & chemotherapy·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Context:

  • Nedaplatin is a platinum-based chemotherapy agent, a derivative of cisplatin.
  • Cisplatin is associated with significant nephrotoxicity and gastrointestinal side effects.
  • There is a need for platinum analogs with improved safety profiles.

Purpose:

  • To evaluate the efficacy and safety of nedaplatin in various advanced cancers.
  • To determine the maximum tolerated dose (MTD) and optimal dosing schedule for nedaplatin.
  • To compare nedaplatin with cisplatin in specific cancer types.

Summary:

  • Phase I study established MTD at 120 mg/m², with bone marrow suppression as the dose-limiting factor.
  • Phase II studies demonstrated response rates ranging from 0% (colon) to 80% (testicular tumors) across multiple cancer types.

Related Experiment Videos

  • Nedaplatin showed comparable efficacy to cisplatin in non-small cell lung cancer (NSCLC) but with significantly reduced nephro and gastrointestinal toxicity, though with increased thrombocytopenia.

    • Impact:

    • Nedaplatin is approved for head and neck, small cell lung cancer (SCLC), NSCLC, esophagus, bladder, testicular, ovarian, and cervical cancers.
    • The recommended dose is 80-100 mg/m² every 4 weeks.
    • Nedaplatin offers a potentially safer alternative to cisplatin for certain malignancies.